Earnings call transcript: Sekisui Chemical Q4 2025 sees mixed results amid market pressures

Sekisui Chemical posted FY2025 net sales of JPY 1,309.3 billion, up JPY 11.5 billion year over year, but operating profit fell to JPY 106.5 billion and missed January guidance amid weak domestic and overseas demand. Ordinary profit rose to JPY 117.2 billion on FX gains, while net income declined to JPY 75.2 billion due to impairment losses. Management guided FY2026 operating profit to JPY 115 billion, raised the annual dividend to JPY 81 per share, and announced a 4 million-share buyback while highlighting a 100 MW perovskite solar cell line for FY2027.

Analysis

The clean read is that Sekisui is becoming more of a cash-allocation story than a pure earnings momentum story: the core portfolio is still growing, but mix and volume are the swing factors, so upside now depends on management proving it can monetize pricing power faster than cost inflation and weak end-demand erode it. The standout second-order effect is that the balance sheet and shareholder-return machinery are getting more aggressive at the same time operating leverage is soft, which means equity returns can improve even if the business only delivers mid-single-digit EBIT growth. That tends to support the stock near trough multiples, but it also raises the risk that buybacks are doing more work than fundamentals over the next two quarters.

The perovskite solar cell push is strategically interesting, but investors should not treat it as an FY26 earnings driver; it is a credibility and option-value catalyst for FY27+. The more important near-term implication is capacity and capex intensity: higher investment into solar film and next-gen products competes with the market’s desire for clean free cash flow, so any execution slip will hit the stock more through sentiment than through near-term EPS. The market is likely underappreciating how much of the current valuation support comes from perceived downside protection via returns, not from durable forecast upgrades.

The geopolitical overlay matters because this is a classic margin-passthrough test: if Middle East disruption pushes feedstock higher, the key variable is timing, not ultimate incidence. Businesses with faster repricing and shorter working-capital cycles should outperform, while exposure to lagged pass-through and project delays becomes a hidden earnings tax over the next 1-2 quarters. In that setup, the crowded trade is to buy the visible dividend story; the better trade is to own the segments with pricing elasticity and avoid assuming the buyback shield can offset a macro input shock indefinitely.

Key Decisions for Investors

• Long 4204 Japan equity on a 3-6 month horizon only on pullbacks toward prior lows; target a 12-15% rebound if management confirms pricing pass-through and the FY26 guidance gap narrows, with a 7-8% stop if the Middle East input-cost shock starts to hit margins.
• Pair trade: long 4204 / short a more feedstock-sensitive Japanese industrial cyclicals basket for 1-2 quarters; thesis is Sekisui’s mix of renewables optionality + buyback support should hold up better than companies with lower pricing power and less capital return.
• Avoid chasing the post-earnings pop; instead, buy 4204 only after the first quarterly update on Middle East cost impact. The asymmetry is better after visibility improves because the stock’s near-term rerating depends on whether the company can truly pass through ~JPY14bn of first-half cost pressure.
• If options are available, buy 3-6 month upside calls financed by selling higher strikes; the setup is a low-conviction, valuation-supported drift higher rather than a breakout trade, so defined-risk convexity is preferable to outright stock.
• For a thematic basket, overweight renewable-enabling materials names with near-term cash returns and underweight pure solar concept names; Sekisui’s perovskite initiative is a better risk-adjusted exposure than chasing unproven solar module beneficiaries.